Video from Rare Disease Congressional Caucus Briefing on PDUFA Now Available

The final Rare Disease Congressional Caucus briefing of 2016 focused on the Prescription Drug User Fee Act (PDUFA), the agreement between the biopharmaceutical industry and Food and Drug Administration (FDA) regarding user fees paid by industry to supplement federal funding for human drug review.

Congress will need to reauthorize PDUFA before the current agreement expires at the end of September 2017, which will be an opportunity to include provisions to encourage the development and streamline the review of rare disease treatments.

Watch the videos to learn more from representatives from debra of America, National Health Council, Biotechnology Innovation Organization, Genentech and office of U.S. Representative Leonard Lance (NJ).

http://rareadvocates.org/driving-innovation-for-lifesaving-therapies-through-pdufa-reauthorization-in-2017/